Docs go from bedside manner to biz manager

Share this article:

Pharmas, and their sales reps, need to understand the health economics of a product in differing contexts, according to panelists at the Pharmaceutical Marketing Research Group's (PMRG) third annual meeting.

Concomitant evolutions—in payer structure, the physician's ability to influence the decision about what is prescribed, and managed care decisions—all effect the way brands should be marketed, said Matt Gray, brand insight director, cornerstone business unit, at AstraZeneca. “A front desk person does a lot more than what they used to do” in terms of decision-making, said Gray, a former sales rep.

“For us to keep walking in and saying ‘our product is better than Y,'” is insufficient, said Gray, adding that reps must be able to talk about how a product can be obtained—via formulary or otherwise—and a description of the outcomes. “It's not going to pay for us to say ‘The pill is blue' anymore,” said Gray.

Scott Schaeffer, a practicing family physician on the panel, said that while a focus on comparative effectiveness and the science behind products is important, a lot of decisions are still made “outside of the algorithm.” Ted Lawrence, CEO at Lawrence & Company, added that product economics aren't the last word, since if that were the case, “all hospital formularies would be the same.”

All the panelists agreed that communicating with an entire practice, on top of single physicians, is reflected in the services requested by clients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?